EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

CYP2C19 ‐Guided Voriconazole Therapy: A Precision Medicine Approach to Mitigate Adverse Effects in Japanese Patients

Yoshiki Katada iD, Daiki Hira iD, Keisuke Umemura iD, Yurie Katsube iD, Hiroki Ishimura, Yusuke Kojima, Machiko Hirai, Moto Kajiwara, Mitsuhiro Sugimoto, Hiroki Endo, Junru Cao, Saki Ohta und 8 weitere

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70317 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Yoshiki Katada und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan. Hauptthemen laut MEDLINE: Antifungal Agents, Chemical and Drug Induced Liver Injury, Cytochrome P-450 CYP2C19, Precision Medicine. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Voriconazole (VRCZ) is a triazole antifungal agent with a broad antifungal spectrum. It is metabolized by hepatic cytochrome P450 (CYP) isozyme CYP2C19, whose genetic polymorphism causes significant variability in drug efficacy and safety. Poor metabolizer alleles of CYP2C19 are more common in Asian populations, increasing the risk of supratherapeutic VRCZ levels. We have developed a novel nomogram based on CYP2C19 genetic polymorphisms. This study aimed to evaluate whether CYP2C19 genotype‐guided VRCZ therapy reduces toxicity in Japanese patients. This retrospective study included 64 patients (genotype‐guided group, n = 26; comparison group, n = 38). The primary outcome was defined as the composite incidence of adverse events commonly observed with VRCZ, represented by the combined occurrence of grade ≥ 2 hepatotoxicity and visual symptoms. Secondary outcomes included the proportion of patients maintaining VRCZ trough concentrations within the therapeutic range (1–4 μg/mL) and the treatment response at 28 days. The composite incidence of adverse events was significantly lower in the genotype‐guided group than in the comparison group ( p = 0.003). VRCZ discontinuation due to adverse events occurred in nine patients (23.7%) in the comparison group and one (3.8%) in the genotype‐guided group ( p = 0.039). More patients in the genotype‐guided group were achieved through concentrations within the therapeutic range at the initial sampling point. However, treatment response rates did not differ significantly between the groups. VRCZ administration based on CYP2C19 genotyping improved therapeutic trough levels management and reduced adverse effects while maintaining therapeutic efficacy. These findings highlight the importance of CYP2C19 genotyping for VRCZ treatment in Japanese patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsChemical and Drug Induced Liver InjuryCytochrome P-450 CYP2C19Precision MedicineVoriconazoleAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedGenotypeJapanNomogramsRetrospective StudiesTreatment OutcomeEast Asian People

Stichwörter der Autor:innen

CYP2C19genotype‐guidedpharmacogenomicsprecision medicinetherapeutic drug monitoringvoriconazole

Substanzen

Antifungal AgentsCYP2C19 protein, humanCytochrome P-450 CYP2C19Voriconazole

Autor:innen und Institutionen

  • Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan.
  • Department of Infection Control and Prevention, Kyoto University Hospital, Kyoto, Japan.
  • Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.
  • Department of Clinical Laboratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

ORCID-Profile: Yoshiki Katada, Daiki Hira, Keisuke Umemura, Yurie Katsube, Masahiro Tsuda, Shunsaku Nakagawa, Koh Shinohara, Yasuhiro Tsuchido, Miki Nagao, Tomohiro Terada

Zitieren

APA

Katada, Y., Hira, D., Umemura, K., Katsube, Y., Ishimura, H., Kojima, Y., Hirai, M., Kajiwara, M., Sugimoto, M., Endo, H., Cao, J., Ohta, S., Kotani, K., Hatazoe, S., Tsuda, M., Nakagawa, S., Shinohara, K., Tsuchido, Y., Nagao, M., & Terada, T. (2025). CYP2C19 ‐Guided Voriconazole Therapy: A Precision Medicine Approach to Mitigate Adverse Effects in Japanese Patients. Clinical and Translational Science. https://doi.org/10.1111/cts.70317

Vancouver

Katada Y, Hira D, Umemura K, Katsube Y, Ishimura H, Kojima Y, et al. CYP2C19 ‐Guided Voriconazole Therapy: A Precision Medicine Approach to Mitigate Adverse Effects in Japanese Patients. Clinical and Translational Science. 2025. doi:10.1111/cts.70317

BibTeX
@article{Katada2025,
  author = {Katada, Yoshiki and Hira, Daiki and Umemura, Keisuke and Katsube, Yurie and Ishimura, Hiroki and Kojima, Yusuke and Hirai, Machiko and Kajiwara, Moto and Sugimoto, Mitsuhiro and Endo, Hiroki and Cao, Junru and Ohta, Saki and Kotani, Kinuka and Hatazoe, Sakiko and Tsuda, Masahiro and Nakagawa, Shunsaku and Shinohara, Koh and Tsuchido, Yasuhiro and Nagao, Miki and Terada, Tomohiro},
  title = {CYP2C19 ‐Guided Voriconazole Therapy: A Precision Medicine Approach to Mitigate Adverse Effects in Japanese Patients},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70317}
}
Kostenlos starten →